ACP supports QPP 032: "Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy" because the measure aligns with the principles of high value care and contributes to improved clinical outcomes as the survivors of a stroke or transient ischemic attack are at increased risk of a subsequent stroke. High-quality evidence exists to support the use of antithrombotic agents for the prevention of a second ischemic stroke in patients who survive an ischemic stroke or transient ischemic attack. We note; however, that the measure specifications do not distinguish among the available antithrombotics, which may encourage prescription of expensive medications. Developers should consider revising the specifications to guide clinicians in making pharmacologic treatment choices that are optimal both clinically and in terms of cost.